VERIGRAFT generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous-like (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogenic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes. VERIGRAFT’s development pipeline comprises products in the areas of vascular regeneration as well as peripheral nerve repair.
Company Details
- Employees
- 16
- Address
- Arvid Wallgrens Backe 20, Gothenburg,sweden 41346,sweden
- in****@****aft.com
- Industry
- Biotechnology
- Website
- verigraft.com
- HQ
- Gothenburg, Sweden
Verigraft Questions
Verigraft's website is verigraft.com
Verigraft's LinkedIn profile is https://se.linkedin.com/company/verigraft
Verigraft has
16 employees.
View email and phone details for 16
employees at Verigraft.
Verigraft's industry is
Biotechnology
Verigraft's top competitors are
Elicera Therapeutics Ab,
Atmp Sweden,
Checkpoint Surgical,
Kimco(Korea Innovative Medicines Consortium),
Ai–bob,
Ektah,
Swan Neurotech,
Excillum,
Epineuron,
Neuraptive Therapeutics, Inc..
Verigraft's support email address is info@verigraft.com
Verigraft's categories are Biotechnology
